FCM
PRAX icon

Farallon Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Farallon Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$3.05M – 181
2024
Q1 		$3.05M Buy
+50,000
New +$2.24M 0.01% 109
2021
Q1 		– Sell
-16,667
Closed -$13.8M – 246
2020
Q4 		$13.8M Buy
+16,667
New +$9.73M 0.08% 99

Other funds holding PRAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Farallon Capital Management's PRAX Position: Q2 2024 in Review

Farallon Capital Management sold out of Praxis Precision Medicines (PRAX) in Q2 2024, closing a stake of 50,000 shares — an estimated $3.05M sold.

Farallon Capital Management first reported a position in PRAX in Q4 2020 and held it in 2 quarters. The position peaked at $13.8M in Q4 2020. 113 funds tracked by Wall St. Rank hold PRAX as of Q2 2024.

  • Farallon Capital Management reported no remaining Praxis Precision Medicines position as of Q2 2024 after selling out during the quarter.
  • Farallon Capital Management sold 50,000 Praxis Precision Medicines shares in Q2 2024, an estimated $3.05M.
  • Farallon Capital Management first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 2 quarters.
  • Farallon Capital Management's Praxis Precision Medicines position peaked at $13.8M in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2024.

Based on Farallon Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.